Health Technology Assessment

A recent issue of Value in Health contains the ISPOR Special Task Force Report on US Value Assessment Frameworks. In this blog post, we summarise the Task Force Report and pick up key points made in the various response articles. We also highlight further OHE work in this area.

A new OHE report discusses NICE’s introduction of a cost-effectiveness threshold to appraise ultra-orphan drugs.

OHE Lunchtime Seminar with Oliver Rivero-Arias on Valuing Children’s Health for Economic Evaluation. 29 March 2018 12:00-2:00pm

A summary of OHE’s activity at the 2018 winter HESG meeting, City, University of London, 10-12th January.

A new paper titled “Challenges in Valuing Temporary Health States for Economic Evaluation: A Review of Empirical Applications of the Chained Time Trade-Off Method” has been published in Value in Health.

This report analyses patient access in the UK to new medicines authorised via the centralised procedure between 2011 and 2016.

OHE has just published a new briefing entitled ‘Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?’

On Tuesday 19th September 2017, Professor Frank Lichtenberg from Columbia University will lead an OHE Lunchtime Seminar on the topic of: How cost-effective are new cancer drugs in the U.S.?

The presentations delivered by OHE at the HTAi Annual Meeting, June 2017, are available in this post.

A new paper, Assessing Value, Budget Impact, and Affordability in Asia, has been published in the International Journal of Technology Assessment in Health Care. This paper summarises the authors’ views on key thoughts and suggestions emerging from the 2016 HTAi Asia Policy Forum (HAPF) meeting.

Pages

Subscribe to RSS - Health Technology Assessment